Domperidone plus magnesium hydroxide and aluminum hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo.

What Was Tested

This randomized controlled trial looks at Aluminum Hydroxide and Domperidone.

At the time of diagnosis and 8 weeks after treatment the patients were clinically evaluated and underwent 24-h continuous esophageal pH monitoring.

Who Took Part

The study group was 80 children.

By PubMed's age tags, the people studied were infants, both men and women.

The patients were randomly divided into four groups: group A was treated with domperidone plus magnesium hydroxide and aluminum hydroxide, group B with domperidone plus alginate, group C with domperidone alone, and group D received placebo.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Aluminum Hydroxide and who got the comparison, which limits bias.

Blinding on both sides kept the children and researchers unaware of who received Aluminum Hydroxide.

A placebo (an inactive look-alike) gave the Aluminum Hydroxide group a baseline to be compared against.

What Was Measured

At the time of diagnosis and 8 weeks after treatment the patients were clinically evaluated and underwent 24-h continuous esophageal pH monitoring.

PubMed files the paper under topics including Aluminum Hydroxide, Domperidone, Esophagus, Gastroesophageal Reflux, Hydrogen-Ion Concentration, Magnesium Hydroxide and Monitoring, Physiologic.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Aluminum Hydroxide and Domperidone in 80 children.

The publication is from 1994 (Scandinavian journal of gastroenterology), a journal based in England.

More context: all human trials.